119 related articles for article (PubMed ID: 25481307)
1. Polymorphic genetic variations of cytochrome P450 19A1 and T-cell leukemia 1A genes in the Tamil population.
Umamaheswaran G; Kadambari D; Kumar AS; Revathy M; Anjana R; Adithan C; Dkhar SA
Environ Toxicol Pharmacol; 2015 Jan; 39(1):102-13. PubMed ID: 25481307
[TBL] [Abstract][Full Text] [Related]
2. Haplotype structures and functional polymorphic variants of the drug target enzyme aromatase (CYP19A1) in South Indian population.
Umamaheswaran G; Dkhar SA; Kalaivani S; Anjana R; Revathy M; Jaharamma M; Shree KM; Kadambari D; Adithan C
Med Oncol; 2013; 30(3):665. PubMed ID: 23893151
[TBL] [Abstract][Full Text] [Related]
3. Genotype, allele and haplotype frequencies of four TCL1A gene polymorphisms associated with musculoskeletal toxicity in the South Indian descent.
Umamaheswaran G; Dkhar SA; Kumar AS; Srinivasa RK; Kadambari D; Adithan C
Bioimpacts; 2014; 4(2):95-100. PubMed ID: 25035853
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms of T- cell leukemia 1A gene loci are not related to the development of adjuvant letrozole-induced adverse events in breast cancer.
Umamaheswaran G; Kadambari D; Muthuvel SK; Kumar NAN; Dubashi B; Aibor Dkhar S; Adithan C
PLoS One; 2021; 16(3):e0247989. PubMed ID: 33760860
[TBL] [Abstract][Full Text] [Related]
5. Association study of aromatase gene (CYP19A1) in essential hypertension.
Shimodaira M; Nakayama T; Sato N; Saito K; Morita A; Sato I; Takahashi T; Soma M; Izumi Y
Int J Med Sci; 2008 Feb; 5(1):29-35. PubMed ID: 18274619
[TBL] [Abstract][Full Text] [Related]
6. Genotypic and allelic variability in CYP19A1 among populations of African and European ancestry.
Starlard-Davenport A; Orloff MS; Dhakal I; Penney RB; Kadlubar SA
PLoS One; 2015; 10(2):e0117347. PubMed ID: 25647083
[TBL] [Abstract][Full Text] [Related]
7. Association of CYP19A1 single-nucleotide polymorphism with digit ratio (2D:4D) in a sample of men and women from Ningxia (China).
Zhanbing M; Jie D; Chunyue B; Hong L; Liang P; Zhenghao H
Early Hum Dev; 2019 May; 132():58-65. PubMed ID: 30986648
[TBL] [Abstract][Full Text] [Related]
8. Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis.
Artigalás O; Vanni T; Hutz MH; Ashton-Prolla P; Schwartz IV
BMC Med; 2015 Jun; 13():139. PubMed ID: 26067721
[TBL] [Abstract][Full Text] [Related]
9. Identification of CYP19A1 single-nucleotide polymorphisms and their haplotype distributions in a Korean population.
Lee SJ; Kim WY; Choi JY; Lee SS; Shin JG
J Hum Genet; 2010 Mar; 55(3):189-93. PubMed ID: 20186154
[TBL] [Abstract][Full Text] [Related]
10. Association between rs10046, rs1143704, rs767199, rs727479, rs1065778, rs1062033, rs1008805, and rs700519 polymorphisms in aromatase (CYP19A1) gene and Alzheimer's disease risk: a systematic review and meta-analysis involving 11,051 subjects.
Song Y; Lu Y; Liang Z; Yang Y; Liu X
Neurol Sci; 2019 Dec; 40(12):2515-2527. PubMed ID: 31278540
[TBL] [Abstract][Full Text] [Related]
11. CYP19A1 rs10046 Pharmacogenetics in Postmenopausal Breast Cancer Patients Treated with Aromatase Inhibitors: One-year Follow-up.
Baatjes K; Peeters A; McCaul M; Conradie MM; Apffelstaedt J; Conradie M; Kotze MJ
Curr Pharm Des; 2020; 26(46):6007-6012. PubMed ID: 32900345
[TBL] [Abstract][Full Text] [Related]
12. Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.
Umamaheswaran G; Kadambari D; Muthuvel SK; Kalaivani S; Devi J; Damodaran SE; Pradhan SC; Dubashi B; Dkhar SA; Adithan C
Breast Cancer Res Treat; 2020 Jul; 182(1):147-158. PubMed ID: 32385792
[TBL] [Abstract][Full Text] [Related]
13. Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial.
Johansson H; Gray KP; Pagani O; Regan MM; Viale G; Aristarco V; Macis D; Puccio A; Roux S; Maibach R; Colleoni M; Rabaglio M; Price KN; Coates AS; Gelber RD; Goldhirsch A; Kammler R; Bonanni B; Walley BA;
Breast Cancer Res; 2016 Nov; 18(1):110. PubMed ID: 27825388
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.
Gervasini G; Jara C; Olier C; Romero N; Martínez R; Carrillo JA
Br J Clin Pharmacol; 2017 Mar; 83(3):562-571. PubMed ID: 27747906
[TBL] [Abstract][Full Text] [Related]
15. Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole.
Lunardi G; Piccioli P; Bruzzi P; Notaro R; Lastraioli S; Serra M; Marroni P; Bighin C; Mansutti M; Puglisi F; Porpiglia M; Ponzone R; Bisagni G; Garrone O; Cavazzini G; Clavarezza M; Del Mastro L
Breast Cancer Res Treat; 2013 Jan; 137(1):167-74. PubMed ID: 23129173
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer.
Napoli N; Rastelli A; Ma C; Yarramaneni J; Vattikutti S; Moskowitz G; Giri T; Mueller C; Kulkarny V; Qualls C; Ellis M; Armamento-Villareal R
Bone; 2013 Aug; 55(2):309-14. PubMed ID: 23643682
[TBL] [Abstract][Full Text] [Related]
17. The impact of CYP19A1 variants and haplotypes on breast cancer risk, clinicopathological features and prognosis.
Alwan AM; Afzaljavan F; Tavakol Afshari J; Homaei Shandiz F; Barati Bagherabad M; Vahednia E; Kheradmand N; Pasdar A
Mol Genet Genomic Med; 2021 Jul; 9(7):e1705. PubMed ID: 34014013
[TBL] [Abstract][Full Text] [Related]
18. CYP19A1 rs2470152 polymorphism increases susceptibility to depression in Chinese Han population.
Yang Y; Yan H; Kong Y; Liu L; Peng Q; Wen Y; Zhou Z; Chang Q
Neurosci Lett; 2019 Nov; 713():134490. PubMed ID: 31518674
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients.
Ferraldeschi R; Arnedos M; Hadfield KD; A'Hern R; Drury S; Wardley A; Howell A; Evans DG; Roberts SA; Smith I; Newman WG; Dowsett M
Breast Cancer Res Treat; 2012 Jun; 133(3):1191-8. PubMed ID: 22418701
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.
Napoli N; Rastelli A; Ma C; Colleluori G; Vattikuti S; Armamento-Villareal R
Pharmacogenet Genomics; 2015 Aug; 25(8):377-81. PubMed ID: 26049585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]